@article{fdi:010009661,
  title = {{I}n vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by {L}eishmania amazonensis},
  author = {{F}ournet, {A}lain and {F}erreira, {M}.{E}. and {R}ojas de {A}rias, {A}. and {T}orres de {O}rtiz, {S}. and {F}uentes, {S}. and {N}akayama, {H}. and {S}chinini, {A}. and {H}ocquemiller, {R}.},
  editor = {},
  language = {{ENG}},
  abstract = {{T}he antileishmanial efficacies of 2-n-propylquinoline, chimanines {B} and {D}, 2-n-pentylquinoline, 2-phenylquinoline, 2-(3,4-methylenedioxyphenylethyl)quinoline, and two total alkaloidal extracts of #{G}alipea longiflora$ were evaluated in {BALB}/c mice infected with #{L}eishmania amazonensis$ or #{L}eishmania venezuelensis$. {A}nimals were treated for 4 to 6 weeks postinfection with a quinoline by the oral route at 50 mg/kg of body weight twice daily for 15 days or by five intralesional injections at intervals of 4 days with a quinoline at 50 mg/kg of body weight. {T}he reference drug, {N}-methylglucamine antimonate ({G}lucantime), was administered by subcutaneous or intralesional injection (regimens of 14, 28, or 56 mg of pentavalent antimony per kg of body weight daily). {T}wice-daily oral treatment with chimanine {B} at 50 mg/kg resulted in a decrease in lesion weight by 70% ({P} < 0.001) and a decrease in the parasite loads by 95% ({P} < 0.001). {F}ive injections of chimanine {B} at intervals of 4 days reduced the lesion weight by 74% and the parasite loads in the lesion by 90% compared with the values for the group of untreated mice. {S}ubcutaneous administration of {N}-methylglucamine antimonate at 28 mg of pentavalent antimony kg per day for 15 days reduced the parasite burden by 95% ({P} < 0.001) and five intralesional injections at the same concentration reduced the parasite burden by 96% ({P} < 0.001). {O}ther 2-substituted quinolines, 2-n-propylquinoline administered by the oral and intralesional routes, 2-phenylquinoline administered by the oral route, 2-n-pentylquinoline administered by intralesional injection, and two total alkaloidal extracts of #{G}. longiflora$ administered by the oral route, had intermediate effects. {T}hese findings suggest that chimanine {B} may be chosen as a lead molecule in the development of oral therapy against leishmaniasis. ({R}{\'e}sum{\'e} d'auteur)},
  keywords = {{LEISHMANIOSE} ; {TRAITEMENT} {MEDICAL} ; {EFFICACITE} ; {ETUDE} {EXPERIMENTALE} ; {PLANTE} {MEDICINALE} ; {ANIMAL} {DE} {LABORATOIRE} ; {QUINOLINE} ; {METHYLGLUCAMINE}},
  booktitle = {},
  journal = {{A}ntimicrobial {A}gents and {C}hemotherapy},
  volume = {40},
  numero = {11},
  pages = {2447--2451},
  ISSN = {0066-4804},
  year = {1996},
  URL = {https://www.documentation.ird.fr/hor/fdi:010009661},
}